# Paul Nathan

Source: https://onco.cc/people/paul-nathan/  
OnCo record `paul-nathan` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma.

## Summary

Paul Nathan (Mount Vernon Cancer Centre) was principal investigator of IMCgp100-202, the randomised trial showing the gp100-directed bispecific T-cell engager tebentafusp improves overall survival in HLA-A*02:01-positive metastatic uveal melanoma, the first drug to do so and the first approved TCR-based therapy. He has led UK melanoma and renal trials and chairs national melanoma guideline groups.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: uveal-melanoma; bispecific; uk
- Role: Consultant Medical Oncologist, Mount Vernon Cancer Centre, London
- Specialisms: Uveal melanoma; Melanoma; Renal cell carcinoma; Bispecific T-cell engagers

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Nathan%20P%5BAuthor%5D%20tebentafusp

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [gp100 (PMEL)](https://onco.cc/targets/gp100/)
- drugs: [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- institutions: [Mount Vernon Cancer Centre](https://onco.cc/institutions/mount-vernon-cancer-centre/)
- trials: [IMCgp100-202](https://onco.cc/trials/imcgp100-202/)

---
JSON: https://onco.cc/api/v1/entities/paul-nathan.json